Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will require driving simulation studies for all new sleep aids and is asking sponsors of currently approved products to conduct such trials. FDA is directing zolpidem-containing product manufacturers to make labeling changes based, in part, on driving data submitted for Transcept’s Intermezzo.
You may also be interested in...
US FDA Gives Sponsors Some Leeway In Studying Drug Effects On Driving
Final guidance on evaluating drug effects on ability to operate a motor vehicle has been slightly modified in response to suggestions by Eisai, Pfizer and Merck.
A Case For Driverless Cars? FDA Draft Guidance Casts Broad Net For Driving Impairment Studies
The folks at Google might find some new investors to support their driverless car project once biopharma sponsors digest a new FDA guidance that outlines an approach to evaluating psychoactive drugs for their potential to affect driving.
Merck’s Suvorexant Driving Claims May Get Green Light After Lunesta Re-Label
FDA signals comfort with declaring low dose of at least one insomnia product as OK for next-day driving, but suvorexant’s fate will depend on Merck’s data.